Overview

Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Status:
Completed
Trial end date:
2001-09-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy followed by peripheral stem cell transplantation or bone marrow transplantation in treating patients who have relapsed or recurrent germ cell cancer.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Temple University
Collaborator:
Fox Chase Cancer Center
Treatments:
Carboplatin
Etoposide
Etoposide phosphate
Criteria
DISEASE CHARACTERISTICS: Documented relapsed or refractory germ cell cancer of the
following sites of origin: Testes Ovary Retroperitoneum Mediastinum Other sites Any stage
of disease allowed Any histologic subtype allowed Seminoma only allowed if ineligible for
radiotherapy Failed to achieve complete remission (CR) following at least 3 courses of a
standard platinum-containing regimen or experienced clear relapse following CR obtained
with such a regimen Absence of tumor markers in the presence of stable residual masses
after initial treatment may be allowed (surgical biopsy should be performed; if medically
safe, to confirm persistence of disease and rule out mature teratoma or fibrosis) Prior CNS
involvement allowed in the absence of gross residual CNS tumor following definitive local
therapy (surgery plus radiotherapy) No gross tumor involvement on bone marrow biopsy

PATIENT CHARACTERISTICS: Age: 15 to 60 Performance status: Karnofsky 80-100% Hematopoietic:
Granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin
less than 2.0 mg/dL SGOT/SGPT less than 2 times normal Albumin greater than 3.0 mg/dL
Renal: Creatinine less than 1.8 mg/dL Cardiovascular: LVEF at least 50% No other serious
cardiac disease that would preclude transplantation Pulmonary: DLCO, FEV1, and FVC at least
50% predicted pO2 at least 70 mm Hg on room air Other: HIV negative No other concurrent
serious psychiatric, neurologic, neoplastic, immunologic, or other medical problem that
would preclude transplantation Not pregnant

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
Characteristics Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics
No prior chest irradiation Surgery: See Disease Characteristics